Propanc Biopharma, Inc.
PPCB· Nasdaq
PPCBPropanc Biopharma, Inc.
Filed May 15, 2023 · 10-Q · 45 days after period end · 0001493152-23-017346
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Net Income | -$809.81K | -$462.69K | -$417.74K | -$2.59M |
| EPS Diluted | -$0.42 | — | -$0.12 | -$348.75 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Propanc Biopharma, Inc. · CIK 1517681 · Engraved from SEC EDGAR
ended Mar 31, 2023 · filed May 15, 2023 · 45 d after period end
